Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6.4% – Should You Buy?

Relay Therapeutics, Inc. (NASDAQ:RLAY)’s share price shot up 6.4% during mid-day trading on Thursday . The company traded as high as $11.18 and last traded at $11.4550. 153,372 shares changed hands during trading, a decline of 94% from the average session volume of 2,388,990 shares. The stock had previously closed at $10.77.

Analyst Ratings Changes

Several research firms have recently commented on RLAY. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Guggenheim upped their target price on Relay Therapeutics from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Wells Fargo & Company raised their target price on Relay Therapeutics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 17th. HC Wainwright lifted their price target on Relay Therapeutics from $14.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. Finally, Citizens Jmp boosted their price target on Relay Therapeutics from $15.00 to $17.00 and gave the company a “market outperform” rating in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Relay Therapeutics has an average rating of “Moderate Buy” and an average price target of $18.00.

Relay Therapeutics Trading Up 15.5%

The business’s 50-day simple moving average is $9.27 and its 200-day simple moving average is $7.76. The company has a market capitalization of $2.22 billion, a PE ratio of -7.70 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $4.34 million. Sell-side analysts forecast that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 13,820 shares of the company’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $105,308.40. Following the sale, the chief financial officer directly owned 250,996 shares of the company’s stock, valued at approximately $1,912,589.52. This represents a 5.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sanjiv Patel sold 43,168 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $7.82, for a total value of $337,573.76. Following the sale, the chief executive officer directly owned 661,041 shares in the company, valued at $5,169,340.62. This represents a 6.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 93,302 shares of company stock valued at $724,355 in the last three months. Company insiders own 4.87% of the company’s stock.

Institutional Trading of Relay Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC raised its position in Relay Therapeutics by 11.9% during the first quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock valued at $956,000 after acquiring an additional 38,812 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Relay Therapeutics by 6.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock valued at $221,000 after acquiring an additional 5,238 shares during the period. Millennium Management LLC boosted its position in Relay Therapeutics by 14.6% in the 1st quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after purchasing an additional 374,491 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Relay Therapeutics in the 1st quarter worth approximately $53,000. Finally, Woodline Partners LP grew its stake in shares of Relay Therapeutics by 448.4% during the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock worth $3,979,000 after purchasing an additional 1,241,657 shares during the period. 96.98% of the stock is owned by institutional investors and hedge funds.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.